We couldn't find that disease.
New combo aims to keep advanced lung cancer in check
NCT ID NCT07141264
First seen Jan 09, 2026
Summary
This study tests whether combining the immunotherapy drug adebrelimab with the chemotherapy drug etoposide (as capsules) can help control extensive-stage small cell lung cancer after initial treatment. About 32 adults in China will receive the combination every three weeks until their cancer worsens. The goal is to see if this maintenance therapy extends the time before the disease progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC,EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital Affiliated to the Fourth Military Medical University
RECRUITINGXi'an, Shannxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab (an immunotherapy drug) combined with etoposide capsules (a chemotherapy drug)
What this could lead to
If successful, this could offer a new maintenance therapy option to help control extensive-stage small cell lung cancer and delay its progression.
What could go wrong
This is a small, early-phase (Phase 2) exploratory study with only 32 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.